David Arthur, Salarius Pharmaceuticals CEO

Salarius Phar­ma­ceu­ti­cals sees with­drawals, 3 of 13 pa­tient re­spon­ders in sar­co­ma tri­al

The Hous­ton-based biotech Salarius Phar­ma­ceu­ti­cals is lift­ing the cov­er on da­ta from a Phase I/II tri­al for a drug cur­rent­ly on vol­un­tary hold af­ter a pa­tient death, and the re­sults ap­pear to have un­der­whelmed in­vestors.

Salarius’ can­di­date, dubbed se­clidem­stat, is an oral LSD1 in­hibitor that is meant to treat Ew­ing sar­co­ma and FET-re­arranged sar­co­mas in pa­tients un­der 12 years old. The biotech had pre­sent­ed da­ta with 13 pa­tients with “first- and sec­ond-re­lapse Ew­ing sar­co­ma” who were treat­ed in com­bi­na­tion with topote­can and cy­clophos­phamide.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.